PCI 3.06.26

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Continue reading

Subsection - Oncology

Essential DMPK Strategies for IND Success

Continue reading

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

Continue reading

Upcoming Events

CPHI 2027
AI in Drug Discovery
DDL 2026
Biotechnology Show 13.02.26

Advertisement

Advertisement

A&M Stabtest April 26

Advertisement

Biopharma Group – 19th March 2025

Advertisement

Micron View

Advertisement

Bachem skyscraper

Advertisement

Fujifilm

Codis Completes Demolition and Begins Construction on PSD-4 Expansion at Haverhill

  • Site preparation milestone moves Codis’ commercial-scale spray drying expansion into the construction phase
  • New GEA Pharma-SD® type PSD-4 will expand solvent-based spray drying capacity for amorphous solid dispersions
  • Investment will utilize existing infrastructure at Haverhill, supporting an efficient route to increased commercial-scale capacity
  • Expansion strengthens Codis’ U.K. pathway from formulation development through to commercial-scale manufacturing

Codis, a global contract development and manufacturing organisation (CDMO) specialising in spray drying, amorphous solid dispersions (ASDs) and advanced particle engineering, today announced a key milestone in the ongoing PSD-4 expansion at the company’s site in Haverhill, U.K.

The demolition of the existing redundant facilities is now complete and makes space for the construction of the new building. The construction milestone marks the next stage of Codis’ investment in a GEA Pharma-SD® type PSD-4 solvent-capable spray dryer. Following installation and validation, the PSD-4 will expand Codis’ commercial-scale solvent-based spray drying capacity for ASDs, enabling pharmaceutical customers to advance poorly soluble drug candidates into larger-scale manufacturing.

Together with the company’s formulation development, analytical, clinical supply and oral solid dose capabilities in Nottingham, the investment will further connect development and manufacturing capabilities across Codis’ U.K. network, supporting programmes as they progress from early formulation through to commercial-scale spray drying.

“Completing demolition and moving into construction is an important milestone for the PSD-4 expansion. By building within our existing Haverhill facility and utilising established site infrastructure, we can deliver the additional capacity efficiently while building on the expertise and capabilities already in place in our 100,000 sq. ft. cGMP facility,” commented Nick Hodgson, Vice President & General Manager, Haverhill Operations.

The PSD-4 expansion remains on schedule, with the next key milestone, the Dryer Factory Acceptance Test (FAT), due to take place in November. The new spray dying capacity is expected to become available in the last quarter of 2027.

About Codis

Codis is a global CDMO specializing in commercial spray drying, amorphous solid dispersions, particle engineering, and finished dose manufacturing for the pharmaceutical, consumer health, nutraceutical, and OTC sectors. With more than 400,000 sq ft of cGMP facilities in St. Louis, Missouri, Seymour, Indiana and Nottingham and Haverhill, UK, Codis combines decades of regulatory expertise, development and manufacturing strength under one brand. Learn more at www.codis.com.

Advertisement

Richter: Wed 23 October 2024, 09:03

Advertisement

Aseptic Tech

Advertisement

Steribar – 12.05.2025

Advertisement

PharmExcel

Advertisement

Polypure hompage

Advertisement

Gen Xpro

Advertisement

Alphinity

Advertisement

Crown Bioscience

Advertisement

Shimadzu

Advertisement

CPC